Definition of at-risk patients : baseline variablesROEHRBORN, Claus G.BJU international (Papier). 2006, Vol 97, pp 7-11, issn 1464-4096, 5 p., SUP2Article

Expert panel debate (1)ROEHRBORN, Claus G.BJU international (Papier). 2006, Vol 97, pp 21-22, issn 1464-4096, 2 p., SUP2Article

Acute relief or future prevention : Is urology ready for preventive health care?ROEHRBORN, Claus G.Urology (Ridgewood, NJ). 2000, Vol 56, Num 5A, pp 12-19, issn 0090-4295Article

Reporting of acute urinary retention in BPH treatment trials: Importance of patient follow-up after discontinuation and case definitionsROEHRBORN, Claus G.Urology (Ridgewood, NJ). 2002, Vol 59, Num 6, pp 811-815, issn 0090-4295Article

Advances in the management of benign prostatic hyperplasiaROEHRBORN, Claus G.Urology (Ridgewood, NJ). 2000, Vol 56, Num 5A, issn 0090-4295, 35 p.Serial Issue

BPH progression : concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONEROEHRBORN, Claus G.BJU international. Supplement (Print). 2008, Vol 101, Num 3, pp 17-21, issn 1465-5101, 5 p.Article

Currently available treatment guidelines for men with lower urinary tract symptomsROEHRBORN, Claus G.BJU international. Supplement (Print). 2008, Vol 102, Num 2, pp 18-23, issn 1465-5101, 6 p.Article

Clinical management of lower urinary tract symptoms with combined medical therapyROEHRBORN, Claus G.BJU international. Supplement (Print). 2008, Vol 102, Num 2, pp 13-17, issn 1465-5101, 5 p.Article

Optimising the management of patients with benign prostatic hyperplasiaROEHRBORN, Claus G; KAPLAN, Steven.BJU international (Papier). 2006, Vol 97, issn 1464-4096, 48 p., SUP2Serial Issue

Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A randomized, placebo-controlled trialROEHRBORN, Claus G.Urology (Ridgewood, NJ). 2001, Vol 58, Num 6, pp 953-959, issn 0090-4295Article

Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention : results of a 2-year placebo-controlled studyROEHRBORN, Claus G.BJU international (Papier). 2006, Vol 97, Num 4, pp 734-741, issn 1464-4096, 8 p.Article

Verification and incorporation biases in studies assessing screening tests: Prostate-specific antigen as an exampleGUPTA, Amit; ROEHRBORN, Claus G.Urology (Ridgewood, NJ). 2004, Vol 64, Num 1, pp 106-111, issn 0090-4295, 6 p.Article

Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: A decision analytical approachLOTAN, Yair; ROEHRBORN, Claus G.The Journal of urology. 2002, Vol 167, Num 1, pp 75-79, issn 0022-5347Article

Definition of at-risk patients : dynamic variablesEMBERTON, Mark.BJU international (Papier). 2006, Vol 97, pp 12-15, issn 1464-4096, 4 p., SUP2Article

Lower urinary tract symptoms and sexual dysfunction : epidemiology and pathophysiologyMCVARY, Kevin.BJU international (Papier). 2006, Vol 97, pp 23-28, issn 1464-4096, 6 p., SUP2Article

LUTS, ED, QOL : Alphabet soup or real concerns to aging men?O'LEARY, Michael P.Urology (Ridgewood, NJ). 2000, Vol 56, Num 5A, pp 7-11, issn 0090-4295Article

The natural history of benign prostatic hyperplasia : What have we learned in the last decade?KIRBY, Roger S.Urology (Ridgewood, NJ). 2000, Vol 56, Num 5A, pp 3-6, issn 0090-4295Article

Assessment of sexual dysfunction in patients with benign prostatic hyperplasiaROSEN, Raymond C.BJU international (Papier). 2006, Vol 97, pp 29-33, issn 1464-4096, 5 p., SUP2Article

Expert panel debate (1)ROEHRBORN, Claus G.BJU international. Supplement (Print). 2006, Vol 97, Num 2, pp 21-22, issn 1465-5101, 2 p.Article

A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men : Focus on the bladder. CommentaryCHAPPLE, Christopher R; ROEHRBORN, Claus G; FICARRA, Vincenzo et al.European urology. 2006, Vol 49, Num 4, pp 651-659, issn 0302-2838, 9 p.Article

Combination of phosphodiesterase-5 inhibitors and α-blockers in patients with benign prostatic hyperplasia : treatments of lower urinary tract symptoms, erectile dysfunction, or both?CARSON, Culley C.BJU international (Papier). 2006, Vol 97, pp 39-43, issn 1464-4096, 5 p., SUP2Article

Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review and meta-analyses. CommentaryLOTAN, Yair; ROEHRBORN, Claus G; HALACHMI, Saral et al.Urology (Ridgewood, NJ). 2003, Vol 61, Num 1, pp 109-118, issn 0090-4295, 10 p.Article

Are all α-blockers created equal? An updateROEHRBORN, Claus G.Urology (Ridgewood, NJ). 2002, Vol 59, Num 2A, pp 3-6, issn 0090-4295Article

Benign prostatic hyperplasiaBARRY, Michael J; ROEHRBORN, Claus G.BMJ. British medical journal (International ed.). 2001, Vol 323, Num 7320, pp 1042-1046, issn 0959-8146Article

Relationships Among Participant International Prostate Symptom Score, Benign Prostatic Hyperplasia Impact Index Changes and Global Ratings of Change in a Trial of Phytotherapy in Men with Lower Urinary Tract SymptomsBARRY, Michael J; CANTOR, Alan; ROEHRBORN, Claus G et al.The Journal of urology. 2013, Vol 189, Num 3, pp 987-992, issn 0022-5347, 6 p.Article